News
AYTU
3.040
-1.30%
-0.040
Weekly Report: what happened at AYTU last week (0318-0322)?
Weekly Report · 4d ago
Weekly Report: what happened at AYTU last week (0311-0315)?
Weekly Report · 03/18 12:30
Weekly Report: what happened at AYTU last week (0304-0308)?
Weekly Report · 03/11 12:24
Weekly Report: what happened at AYTU last week (0226-0301)?
Weekly Report · 03/04 12:29
Weekly Report: what happened at AYTU last week (0219-0223)?
Weekly Report · 02/26 12:50
Weekly Report: what happened at AYTU last week (0212-0216)?
Weekly Report · 02/19 12:52
Maxim Group Remains a Buy on Aytu BioScience (AYTU)
Maxim Group analyst Naz Rahman reiterated a Buy rating on Aytu BioScience yesterday. The company’s shares closed yesterday at $3.12. Rahman covers the Healthcare sector and has an average return of -10.1%. The company reported a quarterly revenue of $22.1 million.
TipRanks · 02/16 12:57
Aytu BioScience GAAP EPS of -$0.04 beats by $0.21, revenue of $22.93M beats by $1.18M
Seeking Alpha · 02/14 21:20
Aytu BioPharma Q2 2024 GAAP EPS $(0.04) Beats $(0.25) Estimate, Sales $22.93M Beat $21.75M Estimate
Aytu BioPharma reported quarterly losses of $0.04 per share. The company also reported quarterly sales of $22.93 million. This is a 12.73 percent decrease over sales of the same period last year. Aytu beat the analyst consensus estimate by 84 percent.
Benzinga · 02/14 21:16
Earnings Scheduled For February 14, 2024
Sony Group is projected to report quarterly earnings at $1.65 per share on revenue of $24.62 billion. CAE and Kraft Heinz are expected to report earnings before the bell. The Chefs' Warehouse is also expected to post earnings for its third quarter. Other companies reporting before the Bell include CNH Industrial and Owens-Corning.
Benzinga · 02/14 09:48
Notable earnings after Wednesday's close
Major earnings expected after the bell on Wednesday include: Cisco Systems (CSCO) Energy Transfer LP (ET) Accidental Petroleum Corporation (OXY) and Albemarle Corporation (ALB) Other earnings slated for release after Wednesday's close include: AT&T (T) and Verizon (VZ)
Seeking Alpha · 02/13 22:35
Aytu BioScience Q2 Earnings Preview
Ayyu BioScience (NASDAQ:AYTU) is scheduled to announce its Q2 earnings results on Wednesday, February 14th. The consensus EPS Estimate is -$0.25 and the consensus revenue estimate is $21.75 million. Aytu BioScience is a biopharmaceutical company.
Seeking Alpha · 02/13 22:20
Earnings Preview: Aytu BioPharma
Aytu BioPharma is set to give its latest quarterly earnings report on Wednesday, 2024-02-14. Analysts estimate the company will report an earnings per share of $-0.25. Shares of Aytu Bio Pharma were trading at $2.93 as of February 12.
Benzinga · 02/13 19:02
Weekly Report: what happened at AYTU last week (0205-0209)?
Weekly Report · 02/12 12:36
Weekly Report: what happened at AYTU last week (0129-0202)?
Weekly Report · 02/05 12:50
Weekly Report: what happened at AYTU last week (0122-0126)?
Weekly Report · 01/29 12:30
Weekly Report: what happened at AYTU last week (0115-0119)?
Weekly Report · 01/22 12:37
Weekly Report: what happened at AYTU last week (0108-0112)?
Weekly Report · 01/15 12:31
Weekly Report: what happened at AYTU last week (0101-0105)?
Weekly Report · 01/08 12:38
Weekly Report: what happened at AYTU last week (1225-1229)?
Weekly Report · 01/01 12:29
More
Webull provides a variety of real-time AYTU stock news. You can receive the latest news about Aytu Biopharma Inc through multiple platforms. This information may help you make smarter investment decisions.
About AYTU
Aytu BioPharma, Inc. is a pharmaceutical company commercializing a portfolio of commercial prescription therapeutics and consumer health products. The Company’s Rx segment consists of prescription pharmaceutical products and the Consumer Health segment consists of various consumer healthcare products (the Consumer Health Portfolio). The Company’s prescription products include Adzenys XR-ODT (amphetamine) extended-release orally disintegrating tablets and Cotempla XR-ODT (methylphenidate) extended-release orally disintegrating tablets for the treatment of attention deficit hyperactivity disorder (ADHD); Karbinal ER (carbinoxamine maleate), an extended-release antihistamine suspension indicated to treat numerous allergic conditions; and Poly-Vi-Flor and Tri-Vi-Flor, two complementary fluoride-based prescription vitamin product lines available in various formulations for infants and children with fluoride deficiency. Its Consumer Health Segment addresses a range of common conditions.